Abstract 50P
Background
Papillary thyroid carcinoma (PTC) has a specific integrin expression signature that correlates with histopathology, specific driver gene mutations, and aggressiveness of the disease. α3β1 integrin is overexpressed, it is involved in PTC cell motility and invasion and is associated with an advanced disease and a worst outcome. Histopathology studies indicate that fibronectin 1 (FN1) and its integrin ligand αVβ3 are overexpressed in PTC. In normal thyroid cells, fibronectin (FN) stimulates DNA synthesis, proliferation and survival through αVβ3 binding.
Methods
The mRNA expression of integrins and FN1 genes in normal thyroid tissues and PTC were assessed in the TCGA database. -The level of FN and αVβ3 in was assessed by immunofluorescence in PTC cell lines (BCPAP, K1) and in a normal thyroid cell line (Nthy-ori3-1). -The release and deposition of FN were estimated by enzyme-linked immunoassay. - The proliferation was measured by MTT assay. -The silencing of gene FN1 in the K1 cell line was performed with KN2.0, non-homology mediated CRISPR knockout kit (ORIGENE®).
Results
Analysis of the TCGA database on 402 PTC and 82 healthy tissues demonstrates that FN1 mRNA is 60 times more expressed in PTC than in healthy tissue and that the ITGAV and ITGB1 subunits are more expressed. The increase in FN1 and ITGAV mRNA expression is associated with metastatic lymph nodes, more advanced staging, extrathyroidal extension, and higher risk. PTC cells show higher expression of integrin αVβ3, the main receptor of FN1 and at the same time a high production of fibronectin. The gene FN1 was silenced in K1 cell line (K1FN1-/-). Both K1 and K1FN1-/- seeded in collagen coated plates attached and survived in the absence of serum. While K1 proliferated under these culture conditions, proliferation was almost absent in K1FN1-/- and was rescued by soluble FN.
Conclusions
Papillary thyroid carcinoma cells express high amounts of αVβ3 integrin and produce more fibronectin. - Fibronectin/ αVβ3 interaction could be a mechanism of disease progression in PTC. - Fibronectin can be a powerful prognostic indicator and a site of pharmacological intervention.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
University of Salerno.
Funding
Department of Medicine, Surgery and Dentistry, University of Salerno.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract